(Q44004637)

English

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma

scientific article published on 12 September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

ChEBI release 2020-05-28

metastatic melanoma

1 reference

based on heuristic

inferred from title

Alexander J. Lazar

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

author name string

Sapna P Patel

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Nicholas E Papadopoulos

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Ping Liu

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Jeffrey R Infante

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Michelle R Glass

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Carol S Vaughn

7

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Patricia M LoRusso

8

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Roger B Cohen

9

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Michael A Davies

10

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Kevin B Kim

11

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

12 September 2012

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

119

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

799-805

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Genetic alterations in signaling pathways in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

21 January 2018

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27790

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.27790

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44004637&oldid=2105566599"